$15.830
-0.256 (-1.62%)Zum Schluss
SMMT-News
SMMT-Events
Summit Therapeutics Collaborates with ECOG-ACRIN on Biliary Tract Cancer Trial
Summit Therapeutics announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer. The new study, EA2251, is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC. The open-label Phase II/III EA2251 study plans to enroll patients in the U.S. who will be randomized to receive ivonescimab in combination with gemcitabine and cisplatin, or pembrolizumab or durvalumab in combination with gemcitabine and cisplatin as the established standard-of-care comparator regimen. The primary endpoint for the study is overall survival. Activation of clinical trial sites is expected to begin in the fourth quarter of 2026.
Summit Therapeutics Options Volume Normal, Implied Volatility at 4.1%
Pre-earnings options volume in Summit Therapeutics is normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 4.1%, or 64c, after results are released. Median move over the past eight quarters is 11.0%.
Summit Therapeutics Initiates Ivonescimab Clinical Trial
Summit Therapeutics (SMMT) announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma. The study is being conducted in collaboration with Summit's partner, Akeso (AKESF). SMT112-216 is a randomized, open-label Phase II clinical study designed to evaluate the safety and efficacy of multiple ivonescimab-based treatment approaches in patients with incurable locally advanced or metastatic ccRCC who have not received prior systemic therapy for advanced disease. The study plans to enroll approximately 100 patients at clinical trial sites in the U.S. and China. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or nivolumab plus ipilimumab as an established standard-of-care comparator regimen.
Summit Therapeutics Closes $2B Investment from AstraZeneca
Summit Therapeutics (SMMT) announced the successful closing of AstraZeneca's (AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approximately 108,955 shares of preferred stock convertible into shares of common stock of Summit at a 1:1,000 ratio. The investment by AstraZeneca totaled $2.0B
Summit Therapeutics Partners with Daiichi Sankyo and AstraZeneca for Clinical Trial
Summit Therapeutics (SMMT) announced a clinical trial collaboration agreement with Daiichi Sankyo (DSNKY) and AstraZeneca (AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway, a TROP2-directed antibody drug conjugate, across multiple solid tumor settings, intending to include breast and lung cancer. The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer. Under the terms of the agreement, each company will contribute their respective therapies for the planned combination trials which will be sponsored by AstraZeneca or Daiichi Sankyo. AstraZeneca, Daiichi Sankyo, and Summit will each contribute to trial costs, and each company will retain development and commercial rights to their respective medicines.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.